Physician
Mat-Su Valley Medical Center LLC
Mat-Su Valley Medical Center LLC was paid $67.36M by Medicaid between Jan 2018 and Dec 2024, across 291 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoMAT-SU VALLEY MEDICAL CENTER LLC
PALMER, AK 99645
PALMER, AK 99645
33aNPI1417975061assigned 07/18/2006
33bProvider typeCardiovascular Disease Physician
28Total paid$67.36M
24GClaims910,178
24DCodes billed291
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 130,313 | $8.55M | |
| 2019 | 132,333 | $9.52M | |
| 2020 | 113,555 | $7.42M | |
| 2021 | 132,545 | $9.93M | |
| 2022 | 131,843 | $11.19M | |
| 2023 | 137,028 | $11.88M | |
| 2024incomplete | 132,561 | $8.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 40,264 | 34,936 | $11.96M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 15,623 | 13,628 | $7.66M |
| G0378 | Hospital observation service, per hour | 9.1% | 7,075 | 5,244 | $6.11M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.6% | 30,536 | 27,398 | $4.46M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 8,091 | 7,332 | $3.32M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.6% | 2,065 | 1,761 | $3.12M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 3.6% | 1,551 | 1,342 | $2.41M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 6,679 | 5,975 | $2.02M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 20,149 | 17,089 | $1.66M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 23,508 | 19,045 | $1.38M |
| 71045 | Radiologic examination, chest; single view | 1.7% | 17,087 | 14,983 | $1.16M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 1,828 | 1,670 | $1.13M |
279 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 15,114 | $1.12M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 8,361 | $864K |
| 59025 | Fetal non-stress test | 1.3% | 2,448 | $844K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 1,130 | $844K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 9,558 | $758K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 2,462 | $754K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,113 | $659K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 758 | $620K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,820 | $618K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,640 | $544K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,816 | $533K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,559 | $495K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,253 | $422K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,104 | $420K |
| 80053 | Comprehensive metabolic panel | <1% | 53,318 | $416K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,902 | $399K |
| 96376 | <1% | 4,198 | $380K | |
| 70498 | <1% | 566 | $362K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,680 | $351K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,953 | $346K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,287 | $332K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 806 | $303K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 51,705 | $297K |
| C1776 | Joint device (implantable) | <1% | 75 | $275K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,956 | $272K |
| 93976 | <1% | 1,839 | $258K | |
| 73130 | <1% | 1,953 | $249K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,643 | $243K |
| 73030 | <1% | 1,867 | $217K | |
| 70496 | <1% | 357 | $214K | |
| 73610 | <1% | 2,143 | $207K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,717 | $189K |
| 93971 | <1% | 1,253 | $185K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,396 | $184K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,541 | $163K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,542 | $147K |
| 73630 | <1% | 1,877 | $130K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,162 | $123K |
| 84484 | <1% | 15,277 | $117K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,721 | $116K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,204 | $115K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 831 | $109K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 295 | $108K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,257 | $97K |
| 73110 | <1% | 1,509 | $97K | |
| 73562 | <1% | 1,908 | $95K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,228 | $94K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,902 | $94K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,898 | $92K |
| 70486 | <1% | 286 | $90K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,882 | $89K |
| 74018 | <1% | 1,460 | $89K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,322 | $88K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,271 | $86K |
| 72100 | <1% | 980 | $79K | |
| C1769 | Guide wire | <1% | 515 | $79K |
| 80306 | <1% | 5,510 | $72K | |
| 85027 | <1% | 14,102 | $69K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,684 | $68K |
| 97597 | <1% | 1,360 | $68K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 573 | $67K |
| 12001 | <1% | 839 | $66K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,334 | $65K |
| 83735 | <1% | 14,266 | $64K | |
| 99223 | Prolong inpt eval add15 m | <1% | 266 | $64K |
| 83690 | <1% | 11,580 | $62K | |
| 10060 | <1% | 561 | $60K | |
| 84703 | <1% | 8,759 | $57K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 202 | $55K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,289 | $52K |
| 82077 | <1% | 4,286 | $52K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,690 | $51K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 517 | $51K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,622 | $48K |
| 87040 | <1% | 6,317 | $48K | |
| 83880 | <1% | 2,150 | $45K | |
| 73140 | <1% | 802 | $44K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,824 | $44K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,036 | $44K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,347 | $43K |
| 81003 | <1% | 24,724 | $43K | |
| 97602 | <1% | 1,432 | $43K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 930 | $42K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 840 | $41K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 246 | $40K |
| 80061 | Lipid panel | <1% | 3,608 | $39K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 467 | $38K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,249 | $37K |
| 90715 | <1% | 1,607 | $37K | |
| 74022 | <1% | 290 | $37K | |
| 73080 | <1% | 454 | $35K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 490 | $35K |
| 80143 | <1% | 2,518 | $33K | |
| 83605 | <1% | 4,497 | $33K | |
| 80179 | <1% | 2,453 | $32K | |
| 84702 | <1% | 2,440 | $32K | |
| 99152 | <1% | 447 | $32K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,252 | $31K |
| 93798 | <1% | 587 | $31K | |
| 97161 | <1% | 825 | $30K | |
| 73502 | <1% | 607 | $30K | |
| 73590 | <1% | 317 | $30K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,030 | $30K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,134 | $29K |
| 87186 | <1% | 4,239 | $29K | |
| 86850 | <1% | 4,383 | $28K | |
| 12002 | <1% | 282 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,743 | $27K |
| 87070 | <1% | 3,877 | $27K | |
| 86803 | <1% | 2,141 | $27K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,705 | $26K |
| 76770 | <1% | 265 | $25K | |
| 81025 | <1% | 3,584 | $25K | |
| 29125 | <1% | 203 | $24K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,920 | $23K |
| 73090 | <1% | 255 | $22K | |
| 84439 | <1% | 3,013 | $22K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,500 | $22K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,690 | $21K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 29 | $21K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,980 | $20K |
| 70491 | <1% | 50 | $20K | |
| 99292 | <1% | 33 | $20K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,778 | $20K |
| 85379 | <1% | 2,643 | $20K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,555 | $20K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,142 | $19K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 147 | $18K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,193 | $18K |
| 87340 | <1% | 2,030 | $18K | |
| 76830 | Ultrasound, transvaginal | <1% | 183 | $18K |
| 76801 | <1% | 189 | $17K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 221 | $17K |
| 82728 | <1% | 1,568 | $17K | |
| 87088 | <1% | 2,889 | $17K | |
| 85730 | <1% | 4,103 | $17K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 27 | $16K |
| 86140 | <1% | 4,281 | $16K | |
| 86920 | <1% | 236 | $16K | |
| 71250 | <1% | 83 | $16K | |
| 85610 | <1% | 5,490 | $16K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,826 | $14K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 73 | $13K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 142 | $13K |
| 87077 | <1% | 1,739 | $13K | |
| 82962 | <1% | 5,765 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 125 | $11K |
| 86900 | <1% | 5,105 | $11K | |
| 86901 | <1% | 5,101 | $11K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,020 | $11K |
| 82607 | <1% | 930 | $11K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,945 | $11K |
| 87430 | <1% | 777 | $11K | |
| 82803 | <1% | 709 | $10K | |
| 94729 | <1% | 112 | $10K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 428 | $10K |
| 94726 | <1% | 98 | $10K | |
| 71101 | <1% | 83 | $9K | |
| 97116 | <1% | 297 | $9K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,345 | $9K |
| 88307 | <1% | 36 | $9K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $9K |
| 87420 | <1% | 679 | $9K | |
| 36430 | <1% | 56 | $9K | |
| 81001 | <1% | 3,227 | $9K | |
| 87210 | <1% | 1,722 | $8K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $8K |
| 12011 | <1% | 127 | $8K | |
| 83540 | <1% | 1,559 | $8K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,530 | $8K |
| 83550 | <1% | 1,110 | $7K | |
| 86141 | <1% | 600 | $7K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 58 | $7K |
| 72040 | <1% | 82 | $7K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 989 | $7K |
| 86592 | <1% | 1,857 | $7K | |
| 87081 | <1% | 1,257 | $7K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 984 | $7K |
| J3490 | Unclassified drugs | <1% | 917 | $7K |
| 85652 | <1% | 3,225 | $7K | |
| 94060 | <1% | 43 | $6K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,376 | $6K |
| 49083 | <1% | 20 | $6K | |
| 86706 | <1% | 607 | $6K | |
| 99221 | <1% | 47 | $6K | |
| 82947 | <1% | 2,407 | $6K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,700 | $6K |
| 82570 | <1% | 1,199 | $5K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 740 | $5K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 481 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 278 | $4K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,718 | $4K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 582 | $4K |
| 96368 | <1% | 61 | $4K | |
| 76870 | <1% | 25 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $4K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 15 | $4K |
| 84100 | <1% | 1,283 | $4K | |
| 80047 | <1% | 469 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 95 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 73 | $4K |
| 84481 | <1% | 223 | $3K | |
| 88342 | <1% | 44 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,258 | $3K |
| 96367 | <1% | 45 | $3K | |
| 86762 | <1% | 210 | $3K | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,014 | $3K |
| 72072 | <1% | 26 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 130 | $2K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 48 | $2K |
| 76937 | <1% | 12 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 62 | $2K |
| 86705 | <1% | 205 | $2K | |
| 84403 | <1% | 91 | $2K | |
| 84156 | <1% | 544 | $2K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 295 | $2K |
| 87653 | <1% | 59 | $2K | |
| 73560 | <1% | 71 | $2K | |
| 84144 | <1% | 96 | $2K | |
| 84550 | <1% | 366 | $1K | |
| 86038 | <1% | 111 | $1K | |
| 82746 | <1% | 126 | $1K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 62 | $1K |
| 87205 | <1% | 343 | $1K | |
| 84112 | <1% | 16 | $1K | |
| 82550 | <1% | 225 | $1K | |
| 29126 | <1% | 12 | $1K | |
| 82784 | <1% | 104 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 36 | $1K |
| 88304 | <1% | 18 | $1K | |
| 85014 | <1% | 578 | $1K | |
| 87075 | <1% | 195 | $964.71 | |
| 90714 | <1% | 52 | $958.06 | |
| J0515 | Injection, benztropine mesylate, per 1 mg | <1% | 32 | $919.82 |
| 82105 | <1% | 54 | $919.37 | |
| 82247 | <1% | 191 | $897.85 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 24 | $807.92 |
| 82565 | <1% | 145 | $737.35 | |
| J7643 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram | <1% | 22 | $640.67 |
| 84145 | <1% | 31 | $536.84 | |
| 83001 | <1% | 36 | $533.22 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 147 | $496.63 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 72 | $489.88 |
| 85007 | <1% | 166 | $486.33 | |
| 80074 | <1% | 13 | $455.78 | |
| 82248 | <1% | 98 | $453.44 | |
| 84520 | <1% | 110 | $438.25 | |
| 51702 | <1% | 14 | $373.63 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 68 | $347.76 |
| 82670 | <1% | 14 | $345.02 | |
| 82950 | <1% | 61 | $329.48 | |
| 82150 | <1% | 41 | $306.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 93 | $277.12 |
| 83970 | <1% | 15 | $274.54 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 307 | $244.98 |
| 84153 | <1% | 15 | $227.11 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 60 | $223.72 |
| 86677 | <1% | 14 | $177.30 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 48 | $155.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,823 | $154.33 |
| 94760 | <1% | 37 | $148.24 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 38 | $122.40 |
| 80069 | <1% | 20 | $122.16 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 42 | $109.01 |
| 84450 | <1% | 16 | $103.98 | |
| 80076 | <1% | 12 | $97.90 | |
| 84460 | <1% | 14 | $93.07 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 12 | $67.98 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,291 | $59.88 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 534 | $35.91 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 13 | $6.89 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 480 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,035 | $0.00 |
| 99001 | 0% | 114 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 16 | $0.00 |
| 36416 | 0% | 19 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 17 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 73 | $0.00 |
| 86364 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.